In today's session, Piramal Pharma experienced a notable surge ... This broad representation across various market segments underscores the company's significance within the Indian equity landscape.

The analysts expressed confidence in Piramal Pharma’s leadership in key products within the CHG segment, which is supported by the company’s backward integration strategy. They anticipate a ...

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the ...

Piramal Critical Care and BrePco Biopharma received UK approval for Neoatricon, a paediatric Dopamine Hydrochloride solution.

Auditor/Auditors for Piramal Pharma Ltd is/are Deloitte Haskins & Sells LLP. In the main management, Nandini Piramal is chairman and Tanya D'Costa is the company secretary for Piramal Pharma Ltd ...

This is a part of the Life Sciences vertical, Bio-Orthopedics division.On 22 April 2010, Piramal Healthcare and Bharat Serums And Vaccines Limited (BSV), an Indian bio-pharmaceutical company ...

India's Piramal Enterprises hit with nearly $172 million tax bill for pharma deal India's Piramal Enterprises said in an exchange filing on Friday that it had received a tax demand of 15.02 ...

Piramal’s issues didn't stop there, with the FDA also noting that the company’s investigations into active pharmaceutical ingredient (API) batch deviations lacked adequate follow-up.

Piramal Pharma Limited stated that Piramal Critical Care (PCC) and Ireland-based BrePco Biopharma Ltd (BPCO) have received approval from UK Medicines and Healthcare Products Regulatory Agency ...

Piramal had acquired stakes in various Shriram companies more than a decade ago, after selling its pharmaceuticals business to Abbott Laboratories in 2010. In recent years, Piramal has sold some ...

Piramal Enterprises Ltd. has received a GST demand notice of Rs 1,502 crore, including tax, interest and penalties, from the Deputy Commissioner of State Tax, Maharashtra. According to an exchange ...

Piramal Enterprises said it has solid grounds to challenge the "unjustified" demand. The company sold its pharmaceutical business and other related units to Piramal Pharma for 44.87 billion rupees in ...